首页> 外文期刊>Fertility and Sterility: Official Journal of the American Fertility Society, Pacific Coast Fertility Society, and the Canadian Fertility and Andrology Society >Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy
【24h】

Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy

机译:子宫内膜异位症的长期医学管理,具有促性腺素和促进促性腺激素释放激素激动剂和加回荷尔酮治疗

获取原文
获取原文并翻译 | 示例
       

摘要

Endometriosis can recur after either surgical or medical therapy. Long-term medical therapy is implemented to treat symptoms or prevent recurrence. Dienogest and gonadotropin-releasing hormone (GnRH) analogues with hormone add-back therapy seem to be equally effective for long-term treatment of pain symptoms associated with endometriosis. There is insufficient evidence to support the superiority of one therapy over the other. However, add-back hormone therapy (HT) is recommended for patients using GnRH agonists. The treatment selection depends on therapeutic effectiveness, tolerability, drug cost, the physician's experience, and expected patient compliance. (C)2017 by American Society for Reproductive Medicine.
机译:子宫内膜异位症可以在手术或医学治疗后重复。 实施长期医疗治疗以治疗症状或预防复发。 具有激素加压治疗的促使蛋白酶和促性腺激素释放激素(GNRH)类似物似乎对与子宫内膜异位症相关的疼痛症状的长期治疗同样有效。 没有足够的证据来支持对另一个治疗的优越性。 然而,建议使用GNRH激动剂的患者加回咯酮治疗(HT)。 治疗选择取决于治疗效果,耐受性,药物成本,医生的经验和预期患者合规性。 (c)2017年由美国生殖医学协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号